Chrysalis BioTherapeutics, Inc. Email Format

Biotechnology ResearchTexas, United States2-10 Employees

Chrysalis BioTherapeutics, Inc. is a privately held biotechnology company based in Galveston, Texas, focused on regenerative therapies that mimic the body's natural signals to activate endothelial progenitor cells and stem cells, promoting tissue repair and restoring function. Incorporated in Delaware in 2012, the company is developing peptide therapeutics, with its lead candidate TP508 originally aimed at accelerating healing of dermal and musculoskeletal injuries and showing potential for diabetic foot ulcers. The program is being advanced for mass casualty injuries, burns, and radiation mitigation, and Chrysalis has demonstrated TP508's ability to mitigate radiation exposure through collaborations with U.S. government agencies on nuclear countermeasure development.

The company operates within biotechnology research, focusing on applications with clinical and defense relevance, supported by government partnerships. In May 2024, Chrysalis was recognized as a Critical Care Therapeutic Innovator and invited to present at a Summit, reflecting its engagement with the clinical and research communities.

Get verified Chrysalis BioTherapeutics, Inc. emails free

Company overview Employee directory